Key Facts & History

The following information shows the summary unaudited pro forma financial information for the combined company.

Exchange/Ticker: NYSE/TSX: VRX
Worldwide Employees: approximately 16,000
Corporate Headquarters: Laval, Quebec, Canada

2013 Full Year Revenues: $5.76 billion
$5.6 billion from product sales
$52.6 million from alliance and royalty revenue
$76.6 million from service and other revenue

2012 Full Year Revenues: $3.48 billion
$3.28 billion from product sales
$105.5 million from alliance and royalty revenue
$86.1 million from service and other revenue


  • Multinational specialty pharmaceutical company
  • Diverse product portfolio with focus on branded pharmaceuticals, branded generics and over-the-counter products
  • Specialization in dermatology and eye health
  • Product sales with focus on North America, Europe and the Middle East, Latin America, Asia Pacific and South Africa
  • Development capability
  • Manufacturing sites in Canada, Brazil, Poland and Mexico
  • Regulatory and medical expertise

Pipeline Highlights

  • Brimonidine (eye whitener) 
  • Vesneo ™  (glaucoma)
  • IDP-118 (plaque psoriasis)
  • Lotemax® Gel Next Gen (post-operative pain and inflammation) 



  • Valeant Completes Acquisition of PreCision Dermatology
  • Valeant Completes Acquisition of Solta Medical


  • Valeant Agrees to Acquire Solta Medical
  • Valeant Completes Acquisition of Bausch + Lomb
  • Medicis Announces Five-Year Aesthetic Collaboration With Mentor
  • Valeant Pharmaceuticals Agrees to Acquire Bausch + Lomb
  • Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
  • Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara®
  • Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape
  • Valeant Pharmaceuticals Acquires Obagi Medical Products, Inc.
  • Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc.
  • Valeant Pharmaceuticals Completes Acquisition of Natur Produkt in Russia


  • Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation
  • Valeant Pharmaceuticals Acquires Visudyne® From QLT
  • Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
  • Valeant Pharmaceuticals Agrees To Acquire OraPharma
  • Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal
  • Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
  • Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Atlantis Pharma in Mexico
  • Valeant Pharmaceuticals to Acquire Pedinol
  • Valeant Moves Its Global Head Office to Quebec and Establish a New Center of Excellence in Dermatology
  • Valeant Pharmaceuticals Agrees to Acquire Natur Produkt in Russia
  • Valeant Pharmaceuticals Agrees to Acquire Certain Assets From Gerot Lannach
  • Valeant to acquire Eyetech
  • Valeant completes divestiture of generic dermatology products to Mylan
  • Valeant acquires Probiotica in Brazil


  • Valeant completes acquisition of iNova
  • Valeant completes acquisition of Dermik
  • Valeant Announces Successful Results From Phase III Onychomycosis Trials
  • Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.
  • Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
  • Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
  • Valeant Announces All-Cash Offer to Acquire Afexa Life Sciences Inc.
  • Valeant Completes Acquisition of Sanitas Group
  • Valeant Announces Approval of Sublinox® in Canada
  • Valeant Announces Distribution Agreement for Zuacta™ in Canada
  • Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
  • Valeant Pharmaceuticals Agrees to Acquire Dermik
  • Meda to License Elidel to Valeant
  • Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
  • GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
  • Valeant Completes Acquisition of PharmaSwiss S.A.
  • Valeant Announces Acquisition of Cholestagel® in Canada
  • Valeant Announces License Of ACZONE(R) (dapsone) Gel 5% In Canada
  • Valeant to Acquire U.S. and Canadian Rights to Zovirax®
  • Valeant to Acquire PharmaSwiss S.A.




  • Valeant Acquires Aton Pharma, Inc.
  • Valeant Announces Regulatory Approval of Onsolis™ in Canada
  • Valeant to Acquire Vital Science Corp. in Canada
  • Valeant Acquires Bunker Industria Farmacêutica Ltda in Brazil
  • Valeant Acquires Instituto Terapêutico Delta Ltda in Brazil
  • Valeant to Acquire Branded Generics/OTC Company in Brazil
  • Valeant Enters Collaboration With Spear Pharmaceuticals
  • Valeant and Biovail Agree to Merge
  • Biovail Enters into License Agreement with Kyowa Hakko Kirin
  • Biovail enters into license and collaboration agreement with Alexza for AZ-004






  • FDA Accepts NDA Filing for Retigabine
  • Valeant to Acquire Laboratoire Dr. Renaud in Canada
  • Valeant to Acquire Polish Products
  • Valeant to Acquire Major Australian Skincare Brands
  • Valeant to Acquire Tecnofarma, A Mexican Generic Company
  • Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana® ER in Canada, Australia and New Zealand
  • Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
  • Acanya™ Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
  • Valeant Completes Acquisition of Dow Pharmaceutical Sciences, Inc.


  • Biovail acquires worldwide rights to Tetrabenazine
  • Biovail acquires U.S. rights to Wellbutrin XL®
  • Biovail Announces Offering of Senior Convertible Notes
  • Biovail Announces U.S. Availability of Aplenzin™ Tablets
  • Biovail Announces Dismissal of Securities Litigation
  • Valeant acquires Dow Pharmaceutical Sciences, Inc.
  • Valeant acquires Dermatech
  • Valeant acquires Coria laboratories, Ltd.
  • Valeant and GlaxoSmithKline announce worldwide collaboration agreement for retigabine
  • Valeant enters into joint venture with Meda AB
  • Valeant sells certain business operations in Europe for $392 million
  • Valeant successfully completes retigabine Phase III epilepsy program validating novel mechanism of action
  • Valeant names J. Michael Pearson as Chairman and Chief Executive Officer
  • Biovail Enters into Commercial Alliance for Aplenzin™
  • Biovail Announces Filing of ANDA for Quetiapine XR Tablets
  • Biovail Announces U.S. Availability of Xenazine® Tablets
  • Biovail Acquires Prestwick Pharmaceuticals
  • Biovail Announces Filing of ANDA for Fenofibrate Tablets
  • Biovail Receives Canadian Approval for Ralivia™ for the Treatment of Moderately Severe Pain
  • Biovail Appoints Peggy Mulligan Chief Financial Officer
  • Biovail Appoints Bill Wells Chief Executive Officer
  • Biovail Announces New Strategic Focus
  • Biovail Receives FDA Approval for Aplenzin (BVF-033)
  • Biovail Receives Canadian Approval for Wellbutrin® XL for the Prevention of Seasonal Major Depressive Illness
  • Valeant signs licensing agreement for Canadian rights to (C)Xyrem® from Jazz Pharmaceuticals
  • Valeant initiates taribavirin Phase 2b clinical study
  • Valeant initiates study of retigabine for pain associated with post-herpetic neuralgia
  • Valeant launches Bedoyecta in the United States
  • Valeant sells Hepatitis-C drug Infergen® to Three Rivers Pharmaceuticals®, LLC
  • Biovail Receives Canadian Approval for Ralivia™
  • Biovail and Depomed Sign License Agreement For Acuform™ Drug-Delivery Technology
  • Wellbutrin XR™ Receives First European Approval
  • Biovail Chairman Eugene Melnyk Announces Retirement
  • Biovail Announces Comprehensive Settlement Related to Wellbutrin XL®
  • Valeant receives FDA approval of Zelapar® for patients with Parkinson's Disease
  • Valeant obtains FDA marketing approval for Cesamet™ to treat nausea and vomiting associated with cancer chemotherapy
  • Kinerase® skincare line is extended and distribution through Nordstrom is launched
  • Valeant launches Zelapar® in the United States for Parkinson's disease
  • Valeant launches Cesamet® in the United States
  • Valeant's worldwide headquarters relocates to Aliso Viejo, California
  • Valeant sells discovery and preclinical assets to Ardea Biosciences
  • Biovail Enters into Exclusive Promotional Agreement for Zovirax®
  • Biovail Eliminates its U.S. Specialty Sales Force
  • Biovail Launches Wellbutrin XL to Canadian Physicians
  • Once Daily ULTRAM® ER Extended-Release Tablets made Available in the United States
  • Biovail Announces Changes to Organizational Structure; Company Realigned into Three Business Units
  • Biovail Names Gilbert Godin Senior Vice-President
  • Biovail Receives Approval for Wellbutrin® XL to Treat Depression in Canada
  • Valeant initiates Phase 3 clinical trials for its epilepsy candidate retigabine
  • Valeant signs agreement with actress Courteney Cox to represent Kinerase® and distributes line to high-end retailer Sephora
  • Valeant acquires Xcel Pharmaceuticals, expanding Valeant's neurology franchise to include Migranal®, Diastat® and epilepsy treatment candidate retigabine
  • Valeant unveils Diastat® AcuDial™ for rapid, at-home treatment of epileptic seizures
  • Valeant completes public offering of 7.2 million shares
  • Timothy T. Tyson appointed President and Chief Executive Officer
  • Biovail Receives FDA Approval for Citalopram ODT
  • Biovail Enters Into Commercial Alliance for Tramadol Products
  • Biovail Launches Glumetza to Canadian Physicians
  • Biovail's Tramadol ER Receives FDA Approval
  • Biovail, Depomed Receive FDA Approval for Extended-Release Glumetza for Type II Diabetes
  • Biovail Realigns U.S. Commercial Organization
  • Biovail Announces $27.6-Million Expansion to Steinbach, Manitoba Manufacturing Facility
  • Biovail Launches Tiazac XC To Canadian Physicians
  • Biovail Receives Approvable Letter for Tramadol ODT
  • Valeant acquires Amarin Pharmaceuticals, Inc., expanding its specialty neurology platform with Zelapar™
  • Valeant acquires global rights to Tasmar®, further building the company's specialty neurology platform
  • Biovail Confirms Receipt of Notification of ANDA Submission for Wellbutrin XL
  • Biovail's Ralivia ER Receives Approvable Letter From FDA
  • Biovail Announces Regulatory Approval of Tiazac XC to Treat Hypertension in Canada
  • Biovail Files NDA For Novel Dosage Form of Anti-Depressant
  • FDA Approves Biovail's Cardizem LA for the Treatment of Angina; New Specialty Sales Force to Promote Additional Angina Indication
  • Biovail NDA For Ralivia ER -- Tramadol Extended Release Tablets -- Accepted for Review
  • Biovail Acquires Rights to Novel Formulations of Eprosartan and Carvedilol
  • ICN and Ribapharm settle litigation with F. Hoffman La-Roche (Roche), which results in licensing the sale of ribavirin to Roche
  • ICN completes the sale of Photonics and Circe units
  • ICN completes the sale of its Russian manufacturing and retail pharmacy operations for $55 million
  • ICN completes the reacquisition of the 20 percent minority interest in Ribapharm, and merges Ribapharm into ICN operations
  • ICN sells Personal Radiation Dosimetry Division to Global Dosimetry Solutions, Inc. for $58 million
  • ICN announces its first direct-to-consumer marketing campaign for Kinerase®
  • ICN changes its name to Valeant Pharmaceuticals International (NYSE:VRX), signifying the core principles and values underpinning the company and its new strategic focus
  • FDA Approves Wellbutrin XL -- New, Once-Daily Antidepressant with Low Risk of Sexual Side Effects and Weight Gain
  • Biovail Submits Cardizem LA NDA for Angina
  • Biovail Announces Receipt of an Approvable Letter for Wellbutrin XL
  • Biovail Acquires Ativan and Isordil from Wyeth
  • Biovail Announces FDA Approval of Teveten HCT for Hypertension
  • FDA Approves Biovail's Cardizem LA for Hypertension
  • Biovail Announces FDA Approval for Zovirax Cream
  • ICN issues IPO for approximately 20 percent interest in subsidiary, Ribapharm Inc.
  • Robert W. O'Leary named Chief Executive Officer and Chairman of the Board of Directors
  • ICN divests operations in Russia, Hungary and Czech Republic, its Biomedicals subsidiary, Photonics business in North America and the Circe unit
  • ICN institutes several new corporate governance initiatives that increase transparency, establish greater Board independence and change the way the company does business
  • Biovail Acquires Canadian Rights to Wellbutrin SR & Zyban From GlaxoSmithKline
  • Biovail Acquires Pharma PASS Companies for $190 Million
  • Biovail Receives FDA Tentative Approval for Flash Dose Zolpidem
  • Biovail's Generic Adalat CC 90mg Receives Final Approval
  • Biovail Receives Approvable Letter for Cardizem XL
  • Biovail Acquires Metformin GR Product Rights From DepoMed
  • Biovail Acquires Vasotec® / Vaseretic® From Merck & Co., Inc.
  • Biovail Acquires Teveten and Teveten HCT U.S. Marketing Rights From Solvay Pharmaceuticals Marketing and Licensing AG
  • Schering-Plough announces FDA approval to market ICN's drug, ribavirin, as REBETOL® capsules for use in combination with PEG-INTRON for chronic hepatitis C
  • Shareholders vote to merge ICN Pharmaceuticals, ICN Biomedicals, SPI Pharmaceuticals and Viratek, Inc. into a single worldwide pharmaceutical company - ICN Pharmaceuticals, Inc.
  • ICN Plaza in Costa Mesa, CA., becomes ICN's international headquarters
  • Sales exceed $100 million as ICN received its first FDA approval for L-dopa
  • Stock trades for the first time on the New York Stock Exchange
  • Major product, ribavirin, is discovered in ICN labs
  • Biovail Receives Hart-Scott-Rodino Approval; Biovail Begins Co-Promotion of Wellbutrin SR Immediately; Initiates 500 Person Sales Force Expansion Program
  • Biovail and GlaxoSmithKline Sign Licensing Agreements for Once Daily Formulation of Wellbutrin and Distribution Rights for Zovirax Ointment & Cream
  • Biovail Completes Cardizem XL NDA Filing
  • Biovail Included in Toronto Stock Exchange --TSE-- 35 Index; Listing to Commence May 11, 2001
  • Biovail Announces Generic Procardia XL 30mg Final Approval, Teva to Launch Product Immediately
  • Biovail Acquires Cardizem Product Lines From Aventis; To Expand U.S. Sales Force to 800; Launch of New Diltiazem Formulation - Cardizem XL - Expected Early 2002
  • Biovail Acquires DJ Pharma - First Direct Foray into the U.S.
  • Biovail Acquires Fuisz Technologies
  • Biovail Enters Into Supply and Distribution Agreement with Teva
  • Biovail Establishes Crystaal - Canadian sales & marketing division
  • Biovail Enters into Supply and Distribution Agreement with Forest Laboratories
  • Biovail launches Steinbach manufacturing operations
  • Company Named Changed to Biovail
  • Trimel Corporation enters field of controlled-release drug-delivery